Net Income (Loss) Attributable to Parent in USD of Arcutis Biotherapeutics, Inc. from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Arcutis Biotherapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to Q3 2025.
  • Arcutis Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was $7.41M.
  • Arcutis Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$44.3M, a 77.3% increase year-over-year.
  • Arcutis Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$140M, a 46.6% increase from 2023.
  • Arcutis Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$262M, a 15.8% increase from 2022.
  • Arcutis Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$311M, a 50.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Arcutis Biotherapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$44.3M $7.41M +$48.9M Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-28
Q2 2025 -$93.3M -$15.9M +$36.4M +69.6% Apr 1, 2025 Jun 30, 2025 10-Q 2025-10-28
Q1 2025 -$130M -$25.1M +$10.3M +29.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-10-28
Q4 2024 -$140M -$10.8M +$55.5M +83.7% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-25
Q3 2024 -$196M -$41.5M +$3.23M +7.21% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-28
Q2 2024 -$199M -$52.3M +$18.7M +26.3% Apr 1, 2024 Jun 30, 2024 10-Q 2025-10-28
Q1 2024 -$217M -$35.4M +$44.7M +55.8% Jan 1, 2024 Mar 31, 2024 10-Q 2025-10-28
Q4 2023 -$262M -$66.3M +$5.74M +7.96% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-25
Q3 2023 -$268M -$44.8M +$62.9M +58.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$331M -$71M -$3.59M -5.32% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$327M -$80.1M -$15.8M -24.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$311M -$72M -$693K -0.97% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-25
Q3 2022 -$311M -$108M -$50.7M -89% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$260M -$67.4M -$25.4M -60.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-03
Q1 2022 -$235M -$64.3M -$28.3M -78.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-03
Q4 2021 -$206M -$71.3M -$37.3M -109% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$169M -$57M -$18.8M -49.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$150M -$42M -$6.6M -18.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$144M -$36M -$8.03M -28.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$136M -$34M -$21.5M -171% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-16
Q3 2020 -$114M -$38.2M -$23.7M -164% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$90.5M -$35.4M -$27.1M -327% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$63.4M -$28M -$21.4M -321% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$42M -$12.6M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-16
Q3 2019 -$14.5M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-16
Q2 2019 -$8.29M Apr 1, 2019 Jun 30, 2019 10-K 2021-02-16
Q1 2019 -$6.66M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-16

Arcutis Biotherapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$140M +$122M +46.6% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 -$262M +$49.3M +15.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 -$311M -$105M -50.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-25
2021 -$206M -$70.7M -52.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 -$136M -$93.7M -223% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$42M -$22.7M -118% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-22
2018 -$19.3M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.